Roswell Park is opening a clinical trial to study the CIMAvax-EGF® vaccine, a cancer treatment that was developed in Cuba. It will be used to treat lung cancer, the most common cause of cancer death worldwide. This vaccine trial is innovative in three significant ways.
Roswell Park made national headlines last April in securing an agreement to bring Cuba’s encouraging lung cancer vaccine, CIMAvax, to the United States for clinical testing. Nearly one year later, Cuba is back in the news and CIMAvax is receiving renewed attention. One of the most frequently asked questions about this vaccine is, “When will it be available for lung cancer patients in the U.S.?”